Clarivate Analytics have created their Alzheimer's Disease insight, which provides an up-to-date assessment of the disease landscape, including its market size, an overview of the burden for clinical development, the competitive intensity of the current and future market, and its unmet medical needs.

Alzheimer's disease (AD) is a slowly progressive and ultimately fatal degenerative brain disorder that the parts of the brain that control thought, memory and language. It is the most common neurodegenerative cause of dementia which is expected to have widespread socioeconomic implications resulting from the combination of high unmet medical need, and aging trend of the global population.

The Insight includes Clarivate's proprietary patient population forecast built around the company's Incidence & Prevalence Database, focusing on the US, the 5EU countries, Japan, and BRIC. In addition to tracking the latest high-profile developments of the assets surrounding the beta-amyloid story, Clarivate Analytics' analysts also provide their opinions on mechanism targets of interest.

Executive summary
 1. Disease background
 2. Market size
  2.1 Epidemiology
  2.2 Financial
 3. Clinical feasibility
  3.1 Biomarkers
  3.2 Preclinical models
  3.3 Clinical trial overview
 4. Competitive Landscape
  4.1 Standards of care algorithms
  4.2 Unmet Needs
 5. Development Landscape
  5.1 Pipeline
  5.2 Key players
  5.3 Promising MOAs
 6. Appendix